Evelo Biosciences Inc
NASDAQ:EVLO
Relative Value
There is not enough data to reliably calculate the relative value of EVLO.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
EVLO Competitors Multiples
Evelo Biosciences Inc Competitors
Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
---|---|---|---|---|---|---|---|---|
US |
Evelo Biosciences Inc
NASDAQ:EVLO
|
793.8k USD | 0 | -0 | 0.2 | 0.2 | ||
US |
Abbvie Inc
NYSE:ABBV
|
287.2B USD | 5.3 | 59.6 | 12.9 | 19.7 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
146.7B USD | 5.2 | 21.8 | 16.3 | 24.4 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
101.2B USD | 10.3 | 28 | 22.3 | 23.4 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
97.4B USD | 7.4 | 24.6 | 16.3 | 17.9 | ||
AU |
CSL Ltd
ASX:CSL
|
133.7B AUD | 6.1 | 35 | 21.2 | 26.3 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
81.2B USD | 3 | 14.3 | 7.9 | 10.2 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
42.1B USD | 6.2 | -8.9 | -9.4 | -8 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
31.1B USD | 3.2 | 26.8 | 14.5 | 18 | ||
KR |
Celltrion Inc
KRX:068270
|
39.2T KRW | 18 | 73.1 | 44.7 | 61.6 |